SITE008-0050

SITE008 (KOR) › SITE008-0050

SITE008-0050

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2025-10-27

completed

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-08 (study day 93); relationship: NOT RELATED

mild assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-06 (study day 91); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 46); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.